[Expression and clinical significance of ZO-1 in patients with non-small cell lung cancer]
- PMID: 21342646
- PMCID: PMC5999770
- DOI: 10.3779/j.issn.1009-3419.2011.02.08
[Expression and clinical significance of ZO-1 in patients with non-small cell lung cancer]
Abstract
Background and objective: It has been proven that the expression of ZO-1 (zonula occluden-1) was correlated with the growth and metastasis of cancer. The aim of this study is to investigate the relationship between ZO-1 gene expression and clinicopathologic parameters and the survival rates in the patients with non-small cell lung cancer (NSCLC).
Methods: The expression levels of ZO-1 gene in 101 patients with NSCLC and lung tissues of 61 patients with benign lung disease were detected by real-time PCR, Western blot and immunohistochemical techniques.
Results: There was a significant statistic difference of ZO-1 mRNA expression levels between carcinoma group and control group (P < 0.01). In carcinoma group, adjacent group and control group, ZO-1 protein expression levels were with significantly statistic difference between each other (P < 0.01 or P < 0.05). There was a significantly statistic difference between ZO-1 mRNA expression levels in survival during 2 years follow-up group and death during 2 years follow-up group (t=-5.61, P < 0.01).
Conclusions: ZO-1 is a valuable predictive marker for NSCLC patients.
背景与目的: 已有的研究表明紧密连接蛋白-1(zonula occluden-1, ZO-1)表达和肿瘤细胞的生长和转移存在密切联系。本研究旨在探讨非小细胞肺癌(non-small cell lung cancer, NSCLC)组织中ZO-1表达的临床意义。
方法: 应用实时荧光定量PCR、Western blot和免疫组化检测101例NSCLC癌组织及癌旁组织中ZO-1 mRNA和蛋白表达,以61例肺部良性病变患者作为对照。
结果: ZO-1 mRNA在癌组织和肺良性病变组织间差异具有统计学意义(P<0.01)。Western blot显示:ZO-1蛋白在癌组织、癌旁组织、肺良性病变组织的相对表达量之间均存在明显差异(P<0.01或P<0.05)。免疫组化显示:ZO-1平均光密度在癌组织、癌旁组织和肺良性病变组织中分别为69.55± 17.13、246.39±83.15、330.93±72.44,组间差异均具有统计学意义(P<0.01)。伴有淋巴结转移与不伴淋巴结转移肺癌组织ZO-1 mRNA表达水平比较有显著性差异(t=-5.07, P<0.01),肺癌患者术后2年内生存组和2年内死亡组间ZO-1 mRNA表达水平比较差异具有统计学意义(t=5.61, P<0.01)。
结论: ZO-1 mRNA和蛋白在NSCLC癌组织中表达降低,并与淋巴结转移的术后生存有密切关系。
Figures


Similar articles
-
Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer.Int J Clin Exp Pathol. 2013 Nov 15;6(12):2887-95. eCollection 2013. Int J Clin Exp Pathol. 2013. PMID: 24294375 Free PMC article.
-
Cytosolic TMEM88 promotes invasion and metastasis in lung cancer cells by binding DVLS.Cancer Res. 2015 Nov 1;75(21):4527-37. doi: 10.1158/0008-5472.CAN-14-3828. Epub 2015 Sep 10. Cancer Res. 2015. PMID: 26359454
-
Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.Int J Clin Exp Pathol. 2015 Jan 1;8(1):601-7. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25755751 Free PMC article.
-
Upregulation of phosphoserine phosphatase contributes to tumor progression and predicts poor prognosis in non-small cell lung cancer patients.Thorac Cancer. 2019 May;10(5):1203-1212. doi: 10.1111/1759-7714.13064. Epub 2019 Apr 11. Thorac Cancer. 2019. PMID: 30977310 Free PMC article.
-
The expression of p33(ING1), p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer.Tumour Biol. 2011 Dec;32(6):1113-21. doi: 10.1007/s13277-011-0211-4. Epub 2011 Jul 22. Tumour Biol. 2011. PMID: 21779982
Cited by
-
Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis.Oncotarget. 2017 Aug 12;8(43):74554-74566. doi: 10.18632/oncotarget.20218. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088807 Free PMC article.
-
Specific expression of ZO-1 and N-cadherin in rosette structures of various tumors: possible recapitulation of neural tube formation in embryogenesis and utility as a potentially novel immunohistochemical marker of rosette formation in pulmonary neuroendocrine tumors.Virchows Arch. 2011 Oct;459(4):399-407. doi: 10.1007/s00428-011-1120-z. Epub 2011 Jul 23. Virchows Arch. 2011. PMID: 21785870
References
-
- Jinn Y, Inase N. Connexin 43, E-cadherin, beta-catenin and ZO-1 expression, and aberrant methylation of the connexin 43 gene in NSCLC. http://europepmc.org/abstract/med/20651379. Anticancer Res. 2010;30(6):2271–2278. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical